Back to results
US 12,741,019 B2Granted
Variant strain-based coronavirus vaccines
AssigneeModernaTX, Inc.
InventorsAndrea Carfi, Guillaume Stewart-Jones, Hamilton Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
Life of this patent
Estimating the term…
Abstract
The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Claims14
A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding an immunogenic SARS-COV-2 Spike(S) protein, wherein the SARS-COV-2 S protein comprises:
- (a) at least 10 of the following mutations:
- A69-70, T951, G142D, ΔY144, R190S, K417N, N439K, E484K, S477N, T478K, N501Y, D614G, H655Y, and P681H, wherein said numbering is based upon the SARS-CoV-2 S protein set forth in SEQ ID NO:20;
- and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:14, or to an immunogenic fragment thereof;
- wherein the mRNA is formulated in lipid nanoparticles, and wherein the mRNA comprises a 5′-cap, a 5′-UTR, a 3′-UTR, a poly(A) sequence, and 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.
1 more element
Dependencies are inferred from the claim text.